|
|
|
|
We find that the effect seen previously is still present and that there is heterogeneity in the amount of decrease in contrast-enhancing lesions.This expanded number of patients and trail design allows for the discussion of new criteria for individual response to treatment,which are applied in the current trial.These approaches may be useful in the examination,early testing,and comparison of experimental therapeutic agents in MS as well as in the characterization of patients who do or do not have a response seen on MRI. |
|